JHVEPhoto/iStock Editorial via Getty Images
- Teva Pharmaceutical (NYSE:TEVA) announced Monday that the U.S. Food and Drug Administration (FDA) accepted its supplemental Biologics License Application aimed at expanding the label of its migraine therapy, Ajovy (fremanezumab-vfrm).
- The injectable prescription medicine is already approved in the U.S. as